The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).
Axel Bex
Consultant or Advisory Role - Pfizer
Thomas Powles
Consultant or Advisory Role - Pfizer
Christian U. Blank
No relevant relationships to disclose
Simon Chowdhury
No relevant relationships to disclose
Simon Horenblas
No relevant relationships to disclose
John Peters
No relevant relationships to disclose
Ekaterini Boleti
No relevant relationships to disclose
John B. A. G. Haanen
Consultant or Advisory Role - Pfizer